• Pasithea Therapeutics published an investor presentation outlining development plans for lead MEK inhibitor candidate PAS-004.
• Clinical program centers on two Phase 1 studies: PAS-004-102 in MAPK-pathway solid tumors, PAS-004-103 in adult NF1 plexiform neurofibromas.
• Interim updates flagged for ESMO Congress 2026 for the cancer study, Q4 2026 for NF1 Part A data covering PN and CN.
• Financial snapshot lists market cap of $19.2 million, cash balance of $45.6 million as of 6/30/26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.